Compare
Passage BIO, Inc. vs Elutia Inc. vs Cardiff Oncology, Inc. vs Sangamo Therapeutics, Inc
| Latest fiscal year | Passage BIO, Inc. PASG | Elutia Inc. ELUTRevenue covers only part of its income (partial revenue) | Cardiff Oncology, Inc. CRDF | Sangamo Therapeutics, Inc SGMOQ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $593.0K | $39.55M |
| Revenue growth (YoY) | n/a | n/a | -13.2% | -31.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | -306.5% |
| Net margin | n/a | n/a | n/m | -310.8% |
| Net income | -$45.52M | $53.38M | -$45.85M | -$122.93M |
| EPS (Diluted) | -$14.35 | $0.87 | -$0.69 | -$0.44 |
| Operating cash flow | -$31.51M | -$44.81M | -$37.92M | -$97.21M |
| Free cash flow | n/a | -$46.69M | -$37.97M | -$97.31M |
| Cash & equivalents | $46.30M | $36.35M | $17.47M | $20.95M |
| Total assets | $62.28M | $62.35M | $61.88M | $59.74M |
| Total liabilities | $43.53M | $34.68M | $16.50M | $74.01M |
| Shareholders' equity | $18.75M | $27.67M | $45.39M | -$14.27M |
| Return on year-end equity | -242.7% | 192.9% | -101.0% | n/a |
| Shares outstanding | 3.18M | n/a | 68.31M | 350.69M |
Revenue, most recent five fiscal years
| Fiscal year | Passage BIO, Inc. | Elutia Inc. | Cardiff Oncology, Inc. | Sangamo Therapeutics, Inc |
|---|---|---|---|---|
| Latest | n/a | n/a | $593.0K Ended 2025-12-31 | $39.55M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $683.0K Ended 2024-12-31 | $57.80M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $488.0K Ended 2023-12-31 | $176.23M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $386.0K Ended 2022-12-31 | $111.30M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $359.0K Ended 2021-12-31 | $110.70M Ended 2021-12-31 |